Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tek antagonists

a technology of antagonists and teks, applied in the field of tek antagonists, can solve problems such as pathological angiogenesis, and achieve the effect of preventing angiogenesis and achieving higher binding affinity

Inactive Publication Date: 2007-02-01
IMMUNEX CORP
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Angiogenesis is stringently regulated under normal conditions, especially in adult animals, and perturbation of the regulatory controls can lead to pathological angiogenesis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tek antagonists
  • Tek antagonists
  • Tek antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

Recombinant Production of Soluble Tek / Fc Fusion Polypeptides

[0116] The molecular cloning of a cDNA encoding the human receptor tyrosine kinase (RTK) Tek (ork, Tie2) is described in U.S. Pat. No. 5,447,860. The Tek cDNA (deposited with the American Type Culture Collection under the terms of the Budapest Treaty on 28 May 1992, Accession No. ATCC 69003) encodes 1124 amino acids, including a signal peptide, an N-terminal extracellular domain, a transmembrane domain, and a C-terminal cytoplasmic domain. Based on sequence analysis, the signal peptide is predicted to encompass residues 1-18, the N-terminal extracellular domain is predicted to encompass residues 19-745, the transmembrane domain is predicted to encompass residues 746-772, and the C-terminal cytoplasmic domain is predicted to encompass residues 773-1124. The extracellular domain includes two immunoglobulin (Ig)-like loops, a region containing three EGF-like cysteine repeats (between residues 211-340), and a region containing...

example 2

Activity of Tek / Fc in a Wound Closure Assay

[0121] A planar endothelial cell migration (wound closure) assay was used to quantitate the inhibition of angiogenesis by Tek / Fc in vitro. In this assay, endothelial cell migration is measured as the rate of closure of a circular wound in a cultured cell monolayer. The rate of wound closure is linear, and is dynamically regulated by agents that stimulate and inhibit angiogenesis in vivo.

[0122] Primary human renal microvascular endothelial cells, HRMEC, were isolated, cultured, and used at the third passage after thawing, as described in Martin et al., In Vitro Cell Dev Biol 33:261, 1997. Replicate circular lesions, “wounds,” (600-800 micron diameter) were generated in confluent HRMEC monolayers using a silicon-tipped drill press. At the time of wounding the medium (DMEM+1% BSA) was supplemented with 20 ng / ml PMA (phorbol-12-myristate-13-acetate), 10 μg / ml Tek472 / Fc, or combinations of 20 ng / ml PMA and 0.001-10 μg / ml Tek472 / Fc. The residua...

example 3

Activity of Tek / Fc in a Corneal Pocket Assay

[0123] A mouse corneal pocket assay was used to quantitate the inhibition of angiogenesis by Tek / Fc in vivo. In this assay, agents to be tested for angiogenic or anti-angiogenic activity are immobilized in a slow release form in a hydron pellet, which is implanted into micropockets created in the corneal epithelium of anesthetized mice. Vascularization is measured as the appearance, density, and extent of vessel ingrowth from the vascularized corneal limbus into the normally avascular cornea.

[0124] Hydron pellets, as described in Kenyon et al., Invest Opthamol. & Visual Science 37:1625, 1996, incorporated sucralfate with bFGF (90 ng / pellet), bFGF and IgG (11 μg / pellet, control), or bFGF and Tek472 / Fc (12.8 μg). The pellets were surgically implanted into corneal stromal micropockets created by micro-dissection 1 mm medial to the lateral corneal limbus of 6-8 week old male C57BL mice. After five days, at the peak of neovascular response to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of pending U.S. application Ser. No. 10 / 357,653 filed Feb. 3, 2003, which is a continuation of pending U.S. application Ser. No. 09 / 733,764, filed Dec. 7, 2000 and incorporated herein by reference, which is a continuation-in-part of U.S. application Ser. No. 09 / 590,656, filed 07 Jun. 2000 and incorporated herein by reference, which claims the benefit of U.S. Provisional Application Ser. No. 60 / 137,889, filed 07 Jun. 1999 and incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates to Tek antagonists and to the use of Tek antagonists to inhibit angiogenesis or other Tek-mediated responses in a mammal. BACKGROUND OF THE INVENTION A. Angiogenesis [0003] Angiogenesis, the generation of new blood vessels, is a spatially and temporally regulated process in which endothelial cells proliferate, migrate, and assemble into tubes, in response to endogenous positive and negative regula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07H21/04C12P21/06C07K14/475C07K16/22C12N15/09A61K31/138A61K31/17A61K31/196A61K31/198A61K31/255A61K31/337A61K31/4164A61K31/475A61K31/513A61K31/519A61K31/555A61K31/7048A61K31/7068A61K33/24A61K38/00A61K38/21A61K38/22A61K38/43A61K45/00A61P27/02A61P35/00C07K14/705C07K14/71C07K16/28C07K19/00C12N5/10C12N15/12C12P21/08
CPCA61K38/00C07K2319/02C07K2319/00C07K14/71A61P27/02A61P35/00
Inventor CERRETTI, DOUGLAS P.BORGES, LUIS G.FANSLOW, WILLIAM C. III
Owner IMMUNEX CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com